This article is more than 5 years old. Information may no longer be current.

Aerpio announces quarterly financial results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerpio Pharmaceuticals posted a net loss of $6 million, or $0.22 per share, in the second quarter of 2018, compared to a net loss of $5.5 million, or $0.21 per share, in the same period of 2017.

General and administrative expenses for the quarter increased 30%, or $0.7 million, while research and development costs went up 33%, or $1.1 million.

The company had cash and cash equivalents of $68.8 million as of June 30, 2018.